Ilexhainanoside D is the main triterpenoid saponin extracted from Ilex hainanensis Merr., and the combination of Ilexhainanoside D and ilexsaponin A1 has anti-inflammation effect^[1].

The combination of Ilexhainanoside D and Ilexsaponin A (60, 120 or 240 mg/kg; for 8 weeks) treatment significantly reduces the severity of non-alcoholic fatty liver disease (NAFLD) induced by high-fat diet in a dose-dependent manner. The combination of Ilexhainanoside D and Ilexsaponin A treatment decreases the ratio of Firmicutes/Bacteroidetes, reduces the relative abundance of Desulfovibrio and increases the relative abundance of Akkermansia. The intestinal barrier is improved as evidenced by the upregulation of the expression of zonula occludens-1 (ZO-1) and occludin in the ileum. The combination of Ilexhainanoside D and Ilexsaponin A treatment reduces the entry of LPS into the circulation and decreases the hepatic gene expression levels of proinflammatory cytokines^[1].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

664.82

C₃₆H₅₆O₁₁

1137648-52-2

海南冬青苷D

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Zhao W, et al. The combination of Ilexhainanoside D and ilexsaponin A1 reduces liver inflammation and improves intestinal barrier function in mice with high-fat diet-induced non-alcoholic fatty liver disease. Phytomedicine. 2019 Jul 26;63:153039.